Compare · AERI vs GILD
AERI vs GILD
Side-by-side comparison of Aerie Pharmaceuticals Inc. (AERI) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AERI and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $155.82B, about 475.5x AERI ($327.7M).
- GILD has hit the wire 20 times in the past 4 weeks while AERI has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 6 for AERI).
- Company
- Aerie Pharmaceuticals Inc.
- Gilead Sciences Inc.
- Price
- $15.25+0.03%
- $125.46-2.11%
- Market cap
- $327.7M
- $155.82B
- 1M return
- -
- -4.46%
- 1Y return
- -
- +13.97%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2013
- 1992
- News (4w)
- 0
- 20
- Recent ratings
- 6
- 25
Aerie Pharmaceuticals Inc.
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest AERI
- SEC Form SC 13G/A filed by Aerie Pharmaceuticals Inc. (Amendment)
- SEC Form 15-12G filed by Aerie Pharmaceuticals Inc.
- Aerie Pharmaceuticals's Return On Capital Employed Overview
- Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business
- SEC Form 4: Mchugh Julie returned $245,449 worth of shares to the company (16,095 units at $15.25), closing all direct ownership in the company to cover taxes
- SEC Form 4: Mcgraw Benjamin F Iii returned $640,256 worth of shares to the company (41,984 units at $15.25), closing all direct ownership in the company to satisfy tax liability
- SEC Form 4: Mcdonnell Peter J returned $121,924 worth of shares to the company (7,995 units at $15.25), closing all direct ownership in the company (for withholding tax)
- SEC Form 4: Kopczynski Casey C. returned $4,273,721 worth of shares to the company (280,244 units at $15.25), closing all direct ownership in the company (withholding tax)
- SEC Form 4: Lang Peter Frederick returned $706,029 worth of shares to the company (46,297 units at $15.25), closing all direct ownership in the company (for withholding tax)
- SEC Form 4: Larocca John returned $817,171 worth of shares to the company (53,585 units at $15.25), closing all direct ownership in the company to satisfy tax liability
Latest GILD
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
- GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
- Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors